Crossmark

Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer

Crossref DOI link: https://doi.org/10.1186/s40425-019-0704-z

Published Online: 2019-08-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dudzinski, Stephanie O.

Cameron, Brent D.

Wang, Jian

Rathmell, Jeffrey C.

Giorgio, Todd D.

Kirschner, Austin N. https://orcid.org/0000-0003-3807-6900
Funding

Funding for this research was provided by:

American Cancer Society (IRG-58-009-56)

SWOG / The Hope Foundation (Impact Award)

National Cancer Institute (5K12CA090625-18, F30 CA224559-01)

National Institute of General Medical Sciences (T32GM007347)
License Information

Text and Data Mining valid from 2019-08-14
More Information

Article History

Received: 26 April 2019

Accepted: 7 August 2019

First Online: 14 August 2019

Ethics approval and consent to participate

: All research involving vertebrate animals was performed in strict accordance with protocols M/14/182 and M1700134 approved by Vanderbilt’s Institutional Animal Care and Use Committee (IACUC). All procedures were conducted according to applicable national guidelines, including appropriate analgesics and anesthesia to ameliorate and minimize animal suffering.

: Not applicable.

: A.N. Kirschner reports receiving commercial research funds from Astellas Pharma Inc., Brainlab Inc., and Augmenix Inc. The other authors declare no potential competing interests.